For years, U.S. combat veterans desperate for relief from post-traumatic stress disorder and traumatic brain injuries have traveled to clinics in Mexico to receive ibogaine, a powerful psychoactive compound derived from an African shrub that is illegal to use medically in the United States. Now, that workaround may be closer to becoming unnecessary. President Trump plans to order a federal review of regulations governing ibogaine with the goal of exploring its potential as a PTSD treatment for veterans, Reuters reported in May 2026. (Reuters has not made the full report available at a permanent URL; the link points to the Reuters homepage because no stable article link has been confirmed. The specific reporters behind the story have not been independently identified.)
No executive order or formal directive has been published, and neither the White House, the Drug Enforcement Administration, nor the Food and Drug Administration has confirmed the review. But the report lands at a moment when one state has already put serious money behind ibogaine research, and early clinical evidence has generated rare bipartisan enthusiasm for a Schedule I substance.
Texas is already spending $50 million on ibogaine trials
Texas has moved faster than any other state to build a legal and financial framework for ibogaine research. Governor Greg Abbott signed Senate Bill 2308 at the Texas Capitol, formally authorizing a state-supported research program targeting ibogaine and related therapies for veterans, according to the governor’s office. The law requires researchers to file an FDA Investigational New Drug application and conduct trials that comply with federal rules, even though ibogaine remains in Schedule I of the Controlled Substances Act.
The state backed that framework with $50 million, awarded through the Health and Human Services Commission to UTMB Health and UTHealth Houston. The two institutions lead a consortium called IMPACT (Ibogaine Medicine for PTSD, Addiction, and Cognitive Trauma), which is designed to run clinical trials covering addiction, traumatic brain injury, and behavioral health conditions in veterans. The award requires non-state matching funds, according to a UTMB Health announcement in December 2025. (No direct link to the UTMB announcement has been confirmed as publicly accessible; the attribution relies on institutional communications referenced in state records.)
Lt. Gov. Dan Patrick and House Speaker Dustin Burrows have said the program was driven by testimony from wounded soldiers and veterans who sought ibogaine treatment abroad because no legal option existed at home. In a joint statement on the program’s progress, they cited those accounts as the catalyst for the $50 million commitment, according to the Office of the Lieutenant Governor. The political energy behind ibogaine in Texas is rooted specifically in veteran advocacy, not in a broader push to legalize psychedelics.
The science so far: promising but preliminary
The clinical evidence most often cited in policy discussions comes from the MISTIC study, a peer-reviewed observational study published in Nature Medicine in 2023. Researchers examined 30 U.S. Special Operations veterans, most with mild traumatic brain injuries, who received ibogaine combined with magnesium at a clinic in Mexico. The study reported meaningful reductions in PTSD, depression, and anxiety symptoms on standardized scales, according to the published paper.
Those results generated significant attention, but the study’s limitations are important. Thirty participants is a small sample. There was no control group, which means placebo effects and selection bias cannot be ruled out. And ibogaine carries known cardiac risks, including the potential to disrupt heart rhythm, with rare but serious adverse events documented in uncontrolled settings over the years.
Separately, an FDA-regulated clinical trial registered as NCT05029401 on ClinicalTrials.gov is studying oral ibogaine for opioid withdrawal, with defined safety, tolerability, and pharmacokinetic endpoints. That trial demonstrates that ibogaine research can proceed under existing federal rules despite Schedule I restrictions, though the licensing and compliance requirements are substantially more burdensome than for drugs in less restrictive schedules.
No large-scale randomized controlled trial has yet established the safety and efficacy profile that the FDA would require for approval. Whether the IMPACT consortium’s trials will produce that level of evidence, and on what timeline, remains an open question. No enrollment figures or interim data have been released publicly since the December 2025 funding announcement.
What a federal review could change, and what it could not
Without official details, the scope of any Trump-ordered review is unclear. It could target rescheduling ibogaine to a less restrictive category, which would reduce the regulatory burden on researchers and potentially allow multi-site trials across state lines. It could focus on loosening DEA research licensing requirements. Or it could pursue a narrower compassionate-use pathway specifically for veterans with treatment-resistant PTSD or traumatic brain injury.
Each of those paths would interact differently with the infrastructure Texas has already built. Rescheduling could accelerate the IMPACT consortium’s work by making it easier to handle the drug and recruit participants. A veteran-only access program, on the other hand, might require Texas researchers to adjust protocols or eligibility criteria. No federal agency has publicly addressed how a regulatory review would affect ongoing or planned ibogaine trials.
It is also unclear whether a review would focus narrowly on ibogaine or fold the drug into a wider reconsideration of psychedelic-assisted therapies. And there is no guarantee that a review would produce binding regulatory changes rather than a report that informs future rulemaking.
What veterans and families should watch for
The practical reality, as of May 2026, is that Texas has set a concrete research program in motion, anchored in federal clinical trial rules and backed by $50 million in public funds. Any nationwide shift in ibogaine policy remains hypothetical until an executive order, agency memorandum, or formal rulemaking notice is published.
Two parallel tracks will determine what happens next. The first is whether federal officials formalize a review of ibogaine regulations and, if so, whether it results in actual rule changes or simply a set of recommendations. The second is whether the Texas-led trials and other FDA-regulated studies can generate the rigorous safety and efficacy data that would be needed for approval.
Only the convergence of those legal and scientific processes would move ibogaine from an experimental compound that veterans seek out in foreign clinics to an approved, broadly accessible treatment in the United States. Until then, the gap between political momentum and clinical proof remains wide, and veterans considering ibogaine should be aware that it is not yet a validated therapy under U.S. law.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
